These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9119317)

  • 1. Application of physiologically based pharmacokinetic modelling to combination toxicology.
    Simmons JE
    Food Chem Toxicol; 1996; 34(11-12):1067-73. PubMed ID: 9119317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of physiologically-based pharmacokinetic/pharmacodynamic dosimetry models for chemical mixtures.
    Yang RS; el-Masri HA; Thomas RS; Constan AA
    Toxicol Lett; 1995 Dec; 82-83():497-504. PubMed ID: 8597101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative structure-pharmacokinetic relationship modelling.
    Fouchécourt MO; Béliveau M; Krishnan K
    Sci Total Environ; 2001 Jul; 274(1-3):125-35. PubMed ID: 11453289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment.
    Andersen ME
    Toxicol Lett; 1995 Sep; 79(1-3):35-44. PubMed ID: 7570672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment.
    el-Masri HA; Thomas RS; Benjamin SA; Yang RS
    Toxicology; 1995 Dec; 105(2-3):275-82. PubMed ID: 8571364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of PBPK modeling in support of the derivation of toxicity reference values for 1,1,1-trichloroethane.
    Lu Y; Rieth S; Lohitnavy M; Dennison J; El-Masri H; Barton HA; Bruckner J; Yang RS
    Regul Toxicol Pharmacol; 2008 Mar; 50(2):249-60. PubMed ID: 18226845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures.
    Yang RS; el-Masri HA; Thomas RS; Constan AA; Tessari JD
    Toxicol Lett; 1995 Sep; 79(1-3):193-200. PubMed ID: 7570656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans.
    Tardif R; Charest-Tardif G; Brodeur J; Krishnan K
    Toxicol Appl Pharmacol; 1997 May; 144(1):120-34. PubMed ID: 9169076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
    Yoon M; Kedderis GL; Yan GZ; Clewell HJ
    Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating pharmacokinetic and pharmacodynamic interactions with computational models in supporting cumulative risk assessment.
    Tan YM; Clewell H; Campbell J; Andersen M
    Int J Environ Res Public Health; 2011 May; 8(5):1613-30. PubMed ID: 21655141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride.
    Delic JI; Lilly PD; MacDonald AJ; Loizou GD
    Regul Toxicol Pharmacol; 2000 Oct; 32(2):144-55. PubMed ID: 11067771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated QSPR-PBPK modelling approach for in vitro-in vivo extrapolation of pharmacokinetics in rats.
    Kamgang E; Peyret T; Krishnan K
    SAR QSAR Environ Res; 2008; 19(7-8):669-80. PubMed ID: 19061083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic analyses of simple mixtures.
    Krishnan K; Clewell HJ; Andersen ME
    Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):151-5. PubMed ID: 7698076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling.
    Yang RS; Thomas RS; Gustafson DL; Campain J; Benjamin SA; Verhaar HJ; Mumtaz MM
    Environ Health Perspect; 1998 Dec; 106 Suppl 6(Suppl 6):1385-93. PubMed ID: 9860897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment.
    Krishnan K; Johanson G
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2005; 23(1):31-53. PubMed ID: 16291521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occupational exposure limits in the context of solvent mixtures, consumption of ethanol, and target tissue dose.
    Dennison JE; Bigelow PL; Andersen ME
    Toxicol Ind Health; 2004 Sep; 20(6-10):165-75. PubMed ID: 15941013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico toxicology: simulating interaction thresholds for human exposure to mixtures of trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane.
    Dobrev ID; Andersen ME; Yang RS
    Environ Health Perspect; 2002 Oct; 110(10):1031-9. PubMed ID: 12361929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically based pharmacokinetic estimated metabolic constants and hepatotoxicity of carbon tetrachloride after methanol pretreatment in rats.
    Evans MV; Simmons JE
    Toxicol Appl Pharmacol; 1996 Oct; 140(2):245-53. PubMed ID: 8887440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrahepatic metabolism by CYP2E1 in PBPK modeling of lipophilic volatile organic chemicals: impacts on metabolic parameter estimation and prediction of dose metrics.
    Yoon M; Madden MC; Barton HA
    J Toxicol Environ Health A; 2007 Sep; 70(18):1527-41. PubMed ID: 17710613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.